Try a new search

Format these results:

Searched for:

in-biosketch:true

person:mazod01

Total Results:

15


Point-of-care routine laboratory testing for patients with suspected viral hemorrhagic fevers

Sullivan, Anne Liston; Jacobson, Jessica L; Dhagat, Priya; DiLorenzo, Madeline; Douyon, Florence; Figueredo, Jamie; Harris, Matthew; Mazo, Dana; Pacheco, Jeffrey; Weston, Gregory; Chan, Justin
When a suspected viral hemorrhagic fever (VHF) case presents to a healthcare facility, healthcare personnel must be able to safely provide initial stabilizing care, which may involve performing basic routine laboratory testing. Current gaps exist in the ability of frontline acute care hospitals to safely perform routine laboratory tests on patients with suspected VHFs that generate category A waste. This review outlines a potential solution for frontline acute care hospitals to perform electrolytes, hemoglobin/hematocrit, and malaria testing, in accordance with National Special Pathogens System guidelines, in the patient's isolation room. We discuss guidance on laboratory risk assessment, equipment considerations, space requirements, staffing solutions, waste management, cost estimates, and remaining challenges. Our manuscript provides frontline acute care hospitals with a potential solution to safely provide a minimum set of routine laboratory tests for patients with suspected VHF.
PMCID:13445462
PMID: 42564991
ISSN: 2732-494x
CID: 6070867

Assessing current capabilities and barriers to performing routine laboratory tests on patients with suspected high consequence infectious disease at frontline acute care hospitals

DiLorenzo, Madeline A; Lo Piccolo, Anthony Joseph; Bosk, Jared; Shapiro-Luft, Dina; Biddinger, Paul; Bhadelia, Nahid; Jausurawong, Tani; Sulmonte, Christopher; Mazo, Dana; Phillips, Michael; Jacobson, Jessica L; Mukherjee, Vikramjit; Chan, Justin
INTRODUCTION/BACKGROUND:Patients with a suspected high-consequence infectious disease (HCID), such as Ebola virus disease, may require routine laboratory testing to guide management. We assessed the capabilities of frontline hospitals and the barriers they face performing laboratory testing for patients with a suspected HCID. METHODS:A one-time confidential REDCap survey querying capabilities to safely perform laboratory tests that the Centers for Disease Control and Prevention considers critical for patients with a suspected HCID was sent to 95 institutions in Baltimore, MD, Boston, MA, New York City, NY, and Washington, DC, from January to May 2025. RESULTS:Fifty (53%) institutions responded, mostly teaching hospitals (96%), with 24% reporting prior experience evaluating a patient with suspected Ebola virus disease. While many hospitals could perform on-site blood gas (70%), hemoglobin/hematocrit (68%), and lactate (68%) tests on a suspected HCID patient, fewer could safely perform a chemistry panel (64%), a urinalysis (60%), a complete blood count with differential (56%), and a malaria rapid diagnostic test (RDT) (48%) on a suspected HCID patient. The five tests respondents most often considered extremely or very important were hemoglobin/hematocrit (91%), chemistry panel (90%), CBC with differential and platelet count (89%), malaria RDT (88%), and blood gas (88%). Reported barriers to performing routine laboratory testing included issues related to patient and staff safety, infection control, lack of appropriate space, and funding. CONCLUSIONS:Our survey identified several barriers to implementing safe laboratory testing. The inability to conduct these laboratory tests may result in delays in care when an HCID is suspected.
PMID: 42204991
ISSN: 1559-6834
CID: 6070378

Clinical Outcomes of Mpox Disease in Patients Treated with Tecovirimat

Leocadio, Ciarra; Garcia, Elizabeth; Lash, Maura; Berardi, Jonathan; Chan, Justin; Chasan, Rachel; Esquivel, Blanca; Foote, Mary; Glesby, Marshall J; Guerra, Amiyah; Harris, Alexander B; Knutsen, Dorothy; Mannheimer, Sharon; Mazo, Dana; McLean, Jacob; McPherson, Tristan; Meyerowitz, Eric; Mgbako, Ofole; Patel, Gopi; Pagán Pirallo, Patricia M; Radix, Asa E; Riska, Paul; Sayegh, Mark; Seifu, Leah; Shaw, Raphael; Zingman, Barry; Zomorodi, Rustin; Zucker, Jason; Wong, Marcia
BACKGROUND:There is emerging literature describing clinical characteristics and outcomes in patients with mpox treated with tecovirimat. METHODS:We analyzed retrospective deidentified data from healthcare systems in New York City with the highest number of tecovirimat prescriptions. Individuals with probable or confirmed mpox initiating tecovirimat from May-December 2022 were included. A chart abstraction instrument was used to extract demographic and clinical data from medical records. We examined factors associated with delay in treatment and hospitalization. RESULTS:A total of 708 individuals prescribed tecovirimat for mpox were included in the analysis; median age was 36 years (IQR 31-43); 566 (80%) were cisgender men who have sex with men; and 399 (56%) were living with HIV. Side effects (100, 14%) and severe adverse events (7, 1%) were rare. The most common long-term sequela was scarring (69, 10%). One hundred and one (14%) were hospitalized. Median time from symptom onset to treatment initiation was 8 days (IQR 6-11). Non-Hispanic Black patients had higher risk of initiating tecovirimat ≥8 days after symptom onset (relative risk [RR]=1.3, 95%CI: 1.2-1.7) and being hospitalized (adjusted relative risk [aRR]=2.2, 95%CI: 1.4-3.5) compared with Hispanic patients, after adjusting for HIV and insurance status. CONCLUSIONS:We described common reasons for tecovirimat initiation and hospitalization. There were racial inequities in hospitalization and treatment delays. More research and focused efforts to mitigate these inequities are needed. These findings may better inform decisions for treatment initiation and hospitalization for mpox.
PMID: 40974008
ISSN: 1537-6591
CID: 5935702

Health insurance status and severe mpox disease outcomes among sexual minority men in NYC: a retrospective cohort study

Mgbako, Ofole; Castellano, Cecilia; Jano, Kathryn; Piccolo, Anthony Lo; DiLorenzo, Madeline A; Knutsen, Dorothy; Shah, Yusra; Pressley, Joyce C; Duncan, Dustin T; Felder, Jason; Mazo, Dana
BACKGROUND:The 2022-2023 global mpox outbreak predominantly affected sexual minority men, with notable racial/ethnic disparities in the USA. While the current literature has established the clinical predictors of severe mpox disease, little is known about the role of insurance status on clinical outcomes. We sought to characterize patients diagnosed with mpox in New York City (NYC) and examine associations between insurance status and mpox severity score (mpox-SS). METHODS:), prior vaccination with JYNNEOS or a smallpox vaccine, presence of a sexually transmitted infection (STI), and CDC Social Vulnerability Index. RESULTS:The mean age (SD) was 38.3 (10.2) years with 53 (37.1%) identifying as non-Hispanic White, 44 (30.8%) as Hispanic/Latino, and 30 (20.9%) as non-Hispanic Black. Over 90% were male sex at birth or identified as cisgender men and approximately 80% were sexual minority men. Ninety-six (67.1%) had private insurance, 6 (4.2%) Medicare, 35 (24.5%) Medicaid, and 4 were (2.8%) uninsured. Sixty-three (44.1%) had a confirmed HIV diagnosis, 25 (17.4%) patients had prior JYNNEOS vaccination, and 31 (21.7%) had a high-risk condition. Thirty-eight (26.6%) patients received tecovirimat; 21 (14.7%) patients were hospitalized, with 4 (2.8%) of those admitted to the ICU. The mean (SD) mpox-SS was 6.85 (3.36). In univariate analysis, lack of insurance or Medicaid status was associated significantly with more severe mpox-SS. Insurance status remained significant (p = 0.03) in multivariable models. CONCLUSIONS:Being uninsured or on Medicaid was significantly associated with a higher mpox-SS in this diverse cohort of predominantly cisgender sexual minority men in NYC. High-risk status and lack of prior vaccination were associated with higher mpox-SS. Further studies are needed to assess the relationship between insurance, delays in access to care, or other socioeconomic inequities with severe mpox to understand the inequities beyond insurance access to prevent disparities in future outbreaks.
PMCID:12239370
PMID: 40629412
ISSN: 1741-7015
CID: 5890732

Antibiotic stewardship bundle for uncomplicated gram-negative bacteremia at an academic health system: a quasi-experimental study

DiPietro, Juliana; Dubrovskaya, Yanina; Marsh, Kassandra; Decano, Arnold; Papadopoulos, John; Mazo, Dana; Inglima, Kenneth; Major, Vincent; So, Jonathon; Yuditskiy, Samuel; Siegfried, Justin
OBJECTIVE/UNASSIGNED:To evaluate whether an antimicrobial stewardship bundle (ASB) can safely empower frontline providers in the treatment of gram-negative bloodstream infections (GN-BSI). INTERVENTION AND METHOD/UNASSIGNED:From March 2021 to February 2022, we implemented an ASB intervention for GN-BSI in the electronic medical record (EMR) to guide clinicians at the point of care to optimize their own antibiotic decision-making. We conducted a before-and-after quasi-experimental pre-bundle (preBG) and post-bundle (postBG) study evaluating a composite of in-hospital mortality, infection-related readmission, GN-BSI recurrence, and bundle-related outcomes. SETTING/UNASSIGNED:New York University Langone Health (NYULH), Tisch/Kimmel (T/K) and Brooklyn (BK) campuses, in New York City, New York. PATIENTS/UNASSIGNED:Out of 1097 patients screened, the study included 225 adults aged ≥18 years (101 preBG vs 124 postBG) admitted with at least one positive blood culture with a monomicrobial gram-negative organism. RESULTS/UNASSIGNED:= 0.043. CONCLUSIONS/UNASSIGNED:GN-BSI bundle worked as a nudge-based strategy to guide providers in VAN DC and increased de-escalation to aminopenicillin-based antibiotics without negatively impacting patient outcomes.
PMCID:11474889
PMID: 39411661
ISSN: 2732-494x
CID: 5718532

Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City

Garcia, Elizabeth A; Foote, Mary M K; McPherson, Tristan D; Lash, Maura K; Bosompem, Amma N; Bouscaren, Alyssa; Chan, Justin; DiLorenzo, Madeline A; Feihel, Dennis; Fowler, Randal C; Gandhi, Vani; Jenny-Avital, Elizabeth R; Kopping, Erik J; Mazo, Dana; McLean, Jacob; Mgbako, Ofole; Sayegh, Mark N; Shaw, Raphael N; Su, Michelle; Meissner, Jeanne Sullivan; Wang, Jade C; Wen, Wendy; Winters, John C; Zeana, Cosmina B; Zucker, Jason; Wong, Marcia
Severe mpox has been observed in people with advanced human immunodeficiency virus (HIV). We describe clinical outcomes of 13 patients with advanced HIV (CD4 <200 cells/μL), severe mpox, and multiorgan involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.
PMCID:11168585
PMID: 38868307
ISSN: 2328-8957
CID: 5668382

Mpox in Children: 3 Cases

Frantzis, Irene; Ungar, Stephanie P; Soma, Vijaya L; Knutsen, Dorothy; Mazo, Dana; Zucker, Jason
Although the 2022 mpox outbreak mostly affected adults, its effect on children and adolescents was also substantial. In this report, we describe the clinical course and treatment of the first 3 known cases of mpox in children in New York City. These cases are instructive because they illustrate various routes of transmission, clinical presentations, and diagnostic challenges that differ from previous reports of mpox in endemic countries and previous mpox outbreaks. Of note is that each of the 3 patients received treatment with tecovirimat under an US Food and Drug Administration expanded access investigational new drug application and improved without exhibiting adverse reactions.
PMID: 38239109
ISSN: 1098-4275
CID: 5627642

Navigating the expanded access investigational new drug protocol for tecovirimat: lessons learned from a public-private hospital partnership during the 2022 NYC mpox outbreak [Editorial]

Mgbako, Ofole; Chan, Justin; Pitts, Robert A; DiLorenzo, Madeline A; Knutsen, Dorothy; Mazo, Dana
During the 2022 mpox outbreak, tecovirimat was accessed through an expanded access investigational new drug (EA-IND) protocol. We leveraged a unique public/private hospital partnership in New York City to create a novel infrastructure to navigate the EA-IND's regulatory requirements and rapidly provide tecovirimat to patients.
PMCID:10369430
PMID: 37502253
ISSN: 2732-494x
CID: 5668372

Utility of incorporation of beta-D-glucan and T2Candida testing for diagnosis and treatment of candidemia

Zacharioudakis, Ioannis M; Zervou, Fainareti N; Marsh, Kassandra; Siegfried, Justin; Yang, Jenny; Decano, Arnold; Dubrovskaya, Yanina; Mazo, Dana; Aguero-Rosenfeld, Maria
The additive role of non-culture-based methods for the diagnosis of candidemia remains unknown. We evaluated 2 clinical practices followed in our hospitals for the diagnosis of candidemia, namely practice#1 including a combination of blood cultures and T2Candida, and practice#2 that also included Beta-D-glucan (BDG). Three out of 96 patients testing positive with practice#1 received a complete antifungal course. Of the 120 patients evaluated with practice#2, 29 were positive. Only 55.2% of those received a complete course. We observed significant differences in antifungal utilization, with 268.5 antifungal days/1000 patient-days for practice#1, as opposed to 371.9 days for practice#2, a nearly 40% difference. However, we found similar rates of antifungal discontinuation among negative patients at 3 days of testing (36.8% and 37.0% respectively). No differences were detected in death and/or subsequent diagnosis of candidemia. In summary, addition of BDG was interpreted variably by clinicians, was associated with an increase in antifungal utilization, and did not correlate with measurable clinical benefits for patients.
PMID: 38071859
ISSN: 1879-0070
CID: 5589412

Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City

Chan, Justin; DiTullio, David J; Pagan Pirallo, Patricia; Foote, Mary; Knutsen, Dorothy; Kottkamp, Angelica Cifuentes; McPherson, Tristan D; Mukherjee, Vikramjit; Pitts, Robert; Wallach, Andrew; Wong, Marcia; Mazo, Dana; Mgbako, Ofole
The 2022 mpox outbreak in New York City posed challenges to rapidly scaling up treatment capacity. We describe a telehealth treatment model launched during this outbreak that facilitated healthcare provider treatment capacity, and was able to adhere to a Centers for Disease Control and Prevention (CDC)-sponsored expanded access investigational new drug (EA-IND) protocol for tecovirimat. Sixty-nine patients were evaluated and prescribed tecovirimat for mpox through telehealth visits at NYC Health + Hospitals/Bellevue and NYU Langone Health from June to August 2022. Thirty-two (46.4%) were previously diagnosed with HIV. Forty-four (63.8%) reported full recovery, with the remainder lost to follow-up. Most patients (n = 60, 87.0%) attended at least one follow-up visit (either in person or through telehealth) after starting treatment. We observed favorable treatment outcomes, with no serious adverse events, hospitalizations, or deaths related to mpox. While equitable access to telehealth remains a limitation that needs to be addressed, this telehealth model enabled a rapid scale-up of tecovirimat prescription during the mpox outbreak, and should be considered as an important tool used to respond to future infectious disease outbreaks.
PMID: 37632124
ISSN: 1758-1109
CID: 5598892